On Tuesday, NovaBay Pharmaceuticals (NYSE: NBY) will release its latest earnings report. Decipher the announcement with Benzinga's help.
Earnings and Revenue
NovaBay Pharmaceuticals EPS will likely be near a loss of 4 cents while revenue will be around $5.97 million, according to analysts.
In the same quarter last year, NovaBay Pharmaceuticals posted a loss of 13 cents per share on sales of $4 million. If the company were to report inline earnings when it publishes results Tuesday, earnings would be up 69.23 percent. Revenue would be up 46.43 percent on a year-over-year basis.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
|Quarter||Q3 2017||Q2 2017||Q1 2017||Q4 2016|
Over the last 52-week period, shares are down 7.89 percent. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.
Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The average rating by analysts on NovaBay Pharmaceuticals stock is a Buy. The validity of this rating has maintained conviction over the past 90 days.
Don't be surprised to see the stock move on comments made during its conference call. NovaBay's Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.
See more from Benzinga
- Steelcase Q4 Earnings Preview
- FedEx Q3 Earnings Preview
- The Market In 5 Minutes: AT&T, Facebook Data, Apple Screens, Google Shopping And More
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.